Lab-Grown Tumor Chips and AI Join Forces to Outsmart Glioblastoma

Glioblastoma, the most aggressive cancer that begins in the brain, has stubbornly resisted decades of progress in oncology. Even with the current standard of care, which combines maximal surgical resection, radiotherapy, and the chemotherapy drug temozolomide, median survival remains measured in months rather than years. A new review published in the Journal of Neuro-Oncology argues that a convergence of two rapidly advancing technologies, ex vivo microphysiological platforms and artificial intelligence, could finally give physicians and patients the personalized, evidence-based treatment guidance that this disease has so sorely lacked. The review, led by researchers spanning the University of Miami, the University of Cincinnati, Tufts Medical Center, and collaborating institutions, lays out a technical roadmap for how laboratory-grown replicas of a patient’s tumor, paired with machine learning algorithms, could transform treatment selection from an educated guess into a data-driven decision.

The core problem the authors address is one of biological complexity. Glioblastoma is not a single disease but a mosaic of genetically and phenotypically distinct cell populations that coexist within the same tumor. Single-cell analyses have revealed remarkable cellular states, including stem-like populations and drug-tolerant persister cells that can survive initial treatment and later seed recurrence. Traditional two-dimensional cell cultures and even many animal models fail to capture this heterogeneity, which is one reason why therapies that look promising in the laboratory routinely fail in clinical trials. Rodent models, while valuable for studying tumor biology and the brain microenvironment, often do not faithfully reproduce the human tumor’s behavior or its response to drugs, and they are slow and expensive to run at the scale needed for individualized medicine.

Ex vivo platforms offer a way around these limitations. These systems take cells or tissue directly from a patient’s surgically removed tumor and grow them outside the body in conditions designed to mimic key aspects of the tumor’s native environment. The review highlights several complementary approaches at different stages of maturity. Patient-derived glioblastoma organoids, three-dimensional self-organizing cultures, have been shown to preserve both the inter-tumoral and intra-tumoral heterogeneity of the original cancers, and recent work has even used them as real-time avatars to test responses to clinical CAR-T cell therapies. Organotypic brain slice cultures maintain the tumor within a fragment of actual brain tissue, preserving interactions with neurons, glia, and immune cells. Microfluidic organ-on-chip systems go further still, incorporating flowing fluid, endothelial barriers that model the blood-brain barrier, and controlled gradients of oxygen and nutrients that shape drug penetration and tumor cell behavior.

Among the platforms the authors examine in detail is a microphysiological system developed to reproduce the phenotypical heterogeneity and drug resistance characteristic of glioblastoma, which can be rapidly biofabricated from patient-derived cells. The review also describes a high-throughput screening strategy that assesses drug cytotoxicity not only in the bulk population of tumor cells but also in the drug-tolerant persister cells that conventional screens tend to miss. This distinction matters because persister cells are increasingly recognized as a central mechanism of relapse across many cancers. A screen that kills the bulk tumor but leaves persisters untouched would paint a dangerously optimistic picture. By quantifying drug effects across both compartments, these assays aim to identify regimens capable of eliminating the full cellular spectrum of the disease. Notably, a randomized clinical trial using a related cancer stem cell assay to guide chemotherapy in recurrent glioblastoma reported improved survival for patients whose treatment was selected by the assay, providing early clinical evidence that functional testing can translate into patient benefit.

Artificial intelligence enters the picture as the analytical engine that can amplify the value of these platforms. Machine learning algorithms excel at finding patterns in large, multidimensional datasets, exactly the kind of data that ex vivo drug screens, genomic profiling, and imaging studies generate. The review outlines how AI approaches can enhance microphysiological platforms at multiple levels. In diagnostics, deep learning models applied to magnetic resonance imaging have reached the point where they can differentiate glioblastoma from lesions that mimic it, and uncertainty-aware ensembles of foundation models have been developed to make such classifications more robust. In treatment planning, AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRI are being used to define radiotherapy targets more accurately than conventional contrast-enhanced imaging allows. Machine learning and deep learning methods have also been applied systematically to prognosis, predicting survival and treatment response from combinations of imaging features and molecular data.

Perhaps the most forward-looking concept the review explores is the integration of drug screen outputs with AI-based modeling to create something approaching a medical digital twin for each patient. In this vision, the results of testing a patient’s tumor cells against a panel of drugs on a chip would be combined with the patient’s genomic, imaging, and clinical data, and machine learning models trained on large cohorts would then predict which regimen offers the best chance of efficacy with acceptable toxicity. Recent work on patient-specific prediction of glioblastoma growth using reduced-order modeling and neural networks demonstrates that computational models can already forecast individual tumor trajectories. A twin-tower architecture that fuses MRI and gene expression data to predict therapy response illustrates how multimodal AI can bridge the gap between laboratory measurements and clinical decisions. The authors suggest that combining efficacy, safety, and pharmacology results from drug screens with the output of extensive AI searches can yield insights that guide physician and patient decision-making and potentially improve prognosis.

The regulatory and scientific landscape appears to be shifting in favor of these human-based technologies. The United States Food and Drug Administration has announced a plan to phase out animal testing requirements for monoclonal antibodies and other drugs, and the National Institutes of Health has stated a priority to fund human-based research technologies. These policy changes could accelerate the adoption of organ-on-chip systems and organoid platforms in preclinical development, and by extension, their use in functional precision medicine. In hematologic cancers, functional precision medicine programs that test drugs against a patient’s living cells have already demonstrated clinical benefit in advanced aggressive disease and have identified exceptional responders, offering a template for what could be achieved in neuro-oncology.

The authors are careful to acknowledge the substantial challenges that remain. Standardization is a major hurdle: organoid cultures can vary between laboratories and even between batches, and microphysiological systems require sophisticated fabrication and handling that are not yet widely available. The turnaround time for growing and testing patient-derived cultures must fit within the narrow window between surgery and the start of adjuvant therapy, typically a matter of weeks. AI models trained on data from one population may not generalize to others, and uncertainty-aware methods are needed to flag when a model’s predictions should be trusted. There are also ethical considerations, including patient privacy, data governance, and the equitable access to technologies that will initially be expensive and concentrated in specialized centers. The review’s authors themselves hold patents and founding roles in companies developing these platforms, underscoring both the commercial momentum behind the field and the importance of independent validation.

What emerges from the review is a coherent argument that neither ex vivo platforms nor AI alone will be sufficient to change the trajectory of glioblastoma care, but that their integration could be transformative. The chip provides the biological ground truth, a living, patient-specific model in which candidate therapies can be tested under physiologically relevant conditions. The AI provides the pattern recognition and predictive power to interpret those results in context, drawing on vast datasets that no individual clinician could assimilate. Together, they promise a form of functional precision medicine in which treatment is selected not by tumor location and histology alone, but by demonstrated response of the patient’s own tumor cells, cross-validated by computational models. For a disease in which the standard regimen has remained essentially unchanged for two decades, and in which nearly every patient eventually relapses, the prospect of rapidly screening combinations that target both the bulk tumor and its drug-tolerant reservoirs represents a genuine shift in approach.

The path from review to routine clinical practice will require prospective trials demonstrating that AI-informed, assay-guided treatment selection improves outcomes beyond current standards, along with the infrastructure to run these platforms at scale. But the pieces are falling into place with unusual speed. Organoid biobanks are being established, organ-on-chip systems are becoming more reproducible and accessible, machine learning models for glioblastoma are advancing through systematic validation, and regulators are signaling openness to alternatives to animal testing. If the integration envisioned by the authors matures as hoped, a patient diagnosed with glioblastoma in the coming years may have their tumor grown on a chip within days of surgery, screened against dozens of drug regimens, and analyzed by algorithms that weigh efficacy, toxicity, and pharmacology to recommend the most promising option. For one of medicine’s most formidable cancers, that would mark the arrival of truly personalized treatment.

Subject of Research: Integration of ex vivo microphysiological platforms and artificial intelligence for personalized glioblastoma treatment selection

Article Title: Integrating ex vivo platforms with AI to guide glioblastoma treatment

Article References: Bardhan, M., Paul, S., Pun, S., Aryal, M. R., Claudio, P. P., Binder, J., Barrile, R., & Krummel, D. A. P. (2026). Integrating ex vivo platforms with AI to guide glioblastoma treatment. Journal of Neuro-Oncology, 179(2), Article 70. https://doi.org/10.1007/s11060-026-05708-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05708-y

Keywords: glioblastoma, artificial intelligence, microphysiological systems, organoids, organ-on-chip, personalized medicine, functional precision medicine, drug screening, machine learning, blood-brain barrier, drug-tolerant persister cells, neuro-oncology